HCV Disease Progression
EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis
- Details
- Category: HCV Disease Progression
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
Probiotics that change the population of organisms in the gut can help improve neurocognitive function and prevent hepatic encephalopathy in people with liver cirrhosis, according to a presentation last month at the EASL International Liver Congress (EASL 2013) in Amsterdam.
Liver Cancer Increasing among People with HIV/HCV Coinfection
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 15 February 2013 00:00
- Written by Liz Highleyman
Hepatocellular carcinoma (HCC) is a growing problem among HIV positive people coinfected with hepatitis C virus (HCV) in Spain, and it is often diagnosed at a late stage when it is difficult to treat, researchers reported in the January 1, 2013, issue of Clinical Infectious Diseases.
HIV+ People Who Get Hepatitis C May Experience Rapid Liver Disease Progression
- Details
- Category: HCV Sexual Transmission
- Published on Tuesday, 08 January 2013 00:00
- Written by Liz Highleyman
People with HIV, especially those with advanced immune suppression, who become coinfected with hepatitis C virus (HCV) may experience rapid progression to decompensated cirrhosis and liver-related death, Mt. Sinai researchers reported in the December 21, 2012, advance edition of Clinical Infectious Diseases.
Hepatitis C Re-treatment with Interferon Monotherapy Provides Little Benefit
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Liz Highleyman
Long-term re-treatment with pegylated interferon monotherapy offers little or no clinical benefit -- even though it may suppress hepatitis C virus (HCV) levels and improve liver fibrosis -- but it can cause adverse events and may be associated with higher mortality, according to a systematic review from the Cochrane Library.
Hepatitis C Cirrhosis Patients with Sustained Treatment Response Have Lower Risk of Death
- Details
- Category: HCV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Hepatitis C patients with cirrhosis who achieve sustained virological response to interferon-based therapy have a reduced risk of all-cause mortality, liver-related death or transplantation, liver cancer, and liver failure compared with non-responders, according to a study described in the December 26, 2012, issue of JAMA.
Web Design and Development by